A replicable longevity medicine model, built with discipline.
Longevilife brings data-driven longevity medicine inside already-authorized clinics, with a capital-light network model. A field validated by the global market, still to be built well in Italy.
The thesis, in three lines.
Medicine is shifting from treating disease to measurable prevention. Premium demand for longevity services is growing structurally.
Today that demand is served poorly: one-off check-ups, aesthetics dressed up as prevention, a fragmented offering, no continuity after the first report.
Longevilife builds an integrated ecosystem — diagnostics, longitudinal data, continuity of care — and makes it replicable inside third-party clinics that are already authorized.
Three forces converging now.
Figures and sources live only on the validation page, always attributed to third parties. Here they stay qualitative.
Structural shift
Medicine is moving from treating disease to measurable prevention. It is a long-term change, not a fad.
Sector capital
International capital is concentrating on measurable-longevity and scalable-prevention models.
Scientific maturity
Biomarkers and indicators validated on large cohorts now make a serious method possible — not promises.
Figures and sources are on the Market validation page.
The Hub model: capital-light and replicable.
The heart of the thesis is not a single center, but a model that enters clinics that are already authorized. Longevilife brings brand, method, protocols, training and operational direction; the partner facility provides spaces, physicians and billing. This sidesteps much of the capital and regulatory risk of building a clinic from scratch, and the model repeats.
Capital-light
It plugs into existing clinical authorizations and spaces, instead of building them from scratch.
Replicable
A defined format, repeatable across multiple facilities without reinventing it each time.
Disciplined
Evidence-based method and anti-hype communication: what lets a serious physician put their name on it.
We are at an early stage. Our strength today is the model, the method and the people — not traction to show off. We write it as we think it.
What kind of operation this is, and what return it seeks.
No figures, but clear from the start: so you can tell whether it's your kind of deal.
It is not a public raise: it is a co-investment in the structure and a selective partnership, on a basis of mutual acquaintance. The group puts skin in the game first.
The expected return has two components: a recurring cash flow from the network of Hubs and pathways, and the value of the assets built over time. Amounts, scope and terms are in the private dossier.
For healthcare groups and strategic operators.
If you represent a healthcare group, a sector operator or a fund weighing a strategic position, the Longevilife model is designed to integrate with existing clinical networks and to scale by replication. We open a private, selective conversation, on a basis of mutual acquaintance.
A project led by people, not by promises.
A team with clinical, scientific and development expertise. Governance distinguishes two roles: scientific direction (scientific vision, method and protocols), at this stage led by the CEO Luca Musella, and an independent medical direction being appointed, registered with the medical board, holding clinical responsibility for the facility. This keeps the clinical role separate from the business role.
The full dossier is private.
The thesis, model, per-format unit economics and project scope are in a dossier we share on qualified request. Access is manual and selective.